Validity of administrative database detection of previously resolved hepatitis B virus in Japan

Imai, Shinobu; Yamana, Hayato; Inoue, Norihiko; Akazawa, Manabu; Horiguchi, Hiromasa; Fushimi, Kiyohide; Migita, Kiyoshi; Yatsuhashi, Hiroshi; Sugiyama, Masaya; Mizokami, Masashi

doi:10.1002/jmv.25540

Cited by 8 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Full‐text articles of 42 studies were retrieved, and six were excluded because they compared aggregate data, validated self‐report questionnaires using claims data as a reference standard, were review articles, were aimed at refining the cancer registry and not for research purposes, did not report case‐defining methods, or did not report a reference standard 12,19–23 . There were 36 eligible studies, including 29 studies 8,10,11,13,24–48 that validated administrative data using an external reference standard and seven studies 9,49–54 that validated administrative data using other data within the same database.…”

Section: Resultsmentioning

confidence: 99%

Validation studies of Japanese administrative health care data: A scoping review

Yamana

Konishi

Yasunaga

2023

Pharmacoepidemiology and Drug

Self Cite

View full text Add to dashboard Cite

Purpose Large‐scale administrative health care databases are increasingly being utilized for research. However, there has not been much literature that validated administrative data in Japan; a previous review identified six validation studies published between 2011 and 2017. We conducted a literature review of studies that assessed the validity of Japanese administrative health care data. Methods We searched for studies published by March 2022 that compared individual‐level administrative data with a reference standard from another data source, as well as studies that validated administrative data using other data within the same database. The eligible studies were also summarized based on characteristics which included data types, settings, reference standard used, numbers of patients, and conditions validated. Results There were 36 eligible studies, including 29 that used external reference standard and seven that validated administrative data using other data within the same database. Chart review was the reference standard in 21 studies (range of the numbers of patients, 72–1674; 11 studies conducted in single institutions and nine studies in 2–5 institutions). Five studies used a disease registry as the reference standard. Diagnoses of cardiovascular diseases, cancer, and diabetes were frequently evaluated. Conclusions Validation studies are being conducted at an increasing rate in Japan, although most of them are small scale. Further large‐scale comprehensive validation studies are necessary to effectively utilize the databases for research.

show abstract

Section: Resultsmentioning

confidence: 99%

Validation studies of Japanese administrative health care data: A scoping review

Yamana

Konishi

Yasunaga

2023

Pharmacoepidemiology and Drug

Self Cite

View full text Add to dashboard Cite

show abstract

“…The NCDA is based on the Standardized Structured Medical Record Information Exchange (SS-MIX), including medical charts, laboratory data, bacterial culture data, and many other data fields on daily basis [ 14 , 15 ]. Additional details have been reported elsewhere [ 12 , 13 , 15 , 16 ].…”

Section: Methodsmentioning

confidence: 99%

Economic and clinical burden from carbapenem-resistant bacterial infections and factors contributing: a retrospective study using electronic medical records in Japan

2022

Self Cite

View full text Add to dashboard Cite

Background Antimicrobial resistance is a major threat to global health and the world economy. The economic burden of carbapenem-resistant infections has not previously been evaluated. We aimed to compare the potential economic burden and clinical outcomes between carbapenem-resistant infections and carbapenem-susceptible infections in Japan. Methods We conducted a retrospective cohort study using electronic medical records. Patients aged 15 years or older and with the diagnosis of pneumonia, urinary tract infection, biliary infection, and sepsis were included. Multivariable regression models with random effects were used to estimate the impact of carbapenem resistance on cost, length of hospital stay, and in-hospital mortality. Results Among the 9,517 patients, 86 (0.9%) had carbapenem-resistant (CR) infections. Compared to carbapenem-susceptible (CS) infections, the patients with the CR infections were significantly more likely to receive mechanical ventilation (37.2 vs. 21.2%, P-value = 0.003), antibiotics (88.4 vs. 63.0%, P-value < 0.001), and especially carbapenem (31.4 vs. 8.3%, P-value < 0.001), before the bacterial culture test positive. Significantly higher median costs were found for the CR infections than the CS infections in the categories of medications (3477 US dollars vs. 1609 US dollars), laboratory tests (2498 US dollars, vs. 1845 US dollars), and hospital stay (14,307 US dollars vs. 10,560 US dollars). In the multivariable regression analysis, the length of stay was 42.1% longer and the cost was 50.4% higher in the CR infections than in the CS infections. The risk of in-hospital mortality did not differ between the two groups (odds ratio 1.24, 95% CI 0.72–2.11), due to the small sample size. The result was robust with a similar trend in the analysis using the inverse probability treatment weighting method. Conclusions Compared to carbapenem-susceptible infections, carbapenem-resistant infections were associated with a higher cost and a longer length of stay. Detailed cost analysis showed significant differences in the categories of medication, laboratory tests, and hospital stay. To our knowledge, this study is the first to assess the potential economic burden of carbapenem-resistant infections using a large hospital-based database.

show abstract

“… 20 Imai et al described the validity of detecting previously resolved hepatitis B virus infection in the NHO database with the chart review as the golden standard, with the positive predictive value (PPV) of 85.8%. 21 In addition, the validation study of comparison with the procedure-based and the diagnosis-based identifications of severe sepsis and disseminated intravascular coagulation in administrative data was conducted. 22 This validation study showed that the procedure-based algorithm is more sensitive than the diagnosis-based algorithm and has the potential to improve the likelihood of disease identification from the NHO database.…”

Section: Data Resource Usementioning

confidence: 99%

Existing Data Sources for Clinical Epidemiology: Database of the National Hospital Organization in Japan

Kanazawa¹,

Tani²,

Imai³

et al. 2022

CLEP

Self Cite

View full text Add to dashboard Cite

This review introduces the National Hospital Organization (NHO) database in Japan. The NHO has maintained two databases through a system of data collection from 140 hospitals in the NHO. National Hospital Organization Clinical Data Archives (NCDA) is collecting clinical information in real time from the electronic medical records since January 2016, and Medical Information Analysis (MIA) databank is collecting daily insurance claims data since April 2010. The NHO database covers more than 8 million patients in 140 hospitals throughout Japan. The database consists of the information of patient profiles, hospital admission and discharge, diagnosis with ICD-10 codes, text data from medical chart, daily health insurance claims such as medical procedures, medications or surgeries, vital signs and laboratory data, and so on. The NHO database includes a wide variety of diseases and settings, including acute, chronic and intractable diseases, emergency medical services, disaster medicine, response to emerging infectious disease outbreaks, medical care according to health policies such as psychiatry, tuberculosis, or muscular dystrophy, and health systems in sparsely populated non-urban areas. Among several common diseases, the database has representativeness in terms of age distribution compared with the Patient Survey 2017 by the Ministry of Health, Labour and Welfare. Interested researchers can contact (700-dbproject@mail.hosp.go.jp) the NHO database division to obtain more information about the NHO database for utilization.

show abstract

Validity of administrative database detection of previously resolved hepatitis B virus in Japan

Cited by 8 publications

References 11 publications

Validation studies of Japanese administrative health care data: A scoping review

Validation studies of Japanese administrative health care data: A scoping review

Economic and clinical burden from carbapenem-resistant bacterial infections and factors contributing: a retrospective study using electronic medical records in Japan

Existing Data Sources for Clinical Epidemiology: Database of the National Hospital Organization in Japan

Contact Info

Product

Resources

About